The impact of insulin-like growth factor-1 on the pattern of cardiac elongation factor-2 variants in a model of overload.

Abstract

Because of its key role in proteosynthesis, the total content of elongation factor-2 (EF-2) and the distribution of six main EF-2 variants were investigated after Pseudomonas Exotoxin A catalyzed [37P]ADP-ribosylation using 1D-PAGE and isoelectric focusing (IEF) in a rat model of hemodynamic overload with variable degrees of cardiac hypertrophy: Chronic NO-synthase inhibition by L-NAME (N-omega-nitro-L-arginine-methyl-ester; 0.75 mg/ml drinking water) induced arterial hypertension without hypertrophy but myocardial apoptosis; additional treatment with IGF-1 (osmotic micropumps) did not modify hypertension but reduced apoptosis allowing moderate hypertrophy of the left ventricles. Total EF-2 did not significantly increase in rats with hemodynamic overload with or without IGF-1 supplementation. A positive correlation was found between an acidic EF-2 variant and apoptosis (p = 0.01). Hypertrophy under additional IGF-1 was combined with a shift of the EF-2 variants to basic subtypes (p < 0.01). This finding may be indicative of the trophic potency of IGF-1.

• Authors: Doris Jäger, Ursula Müller-Werdan, Klaus Pönicke, Jürgen Holtz, Karl Werdan, Sylvana P Müller
• Journal: Molecular and cellular biochemistry (Mol Cell Biochem) Vol. 229 Issue 1-2 Pg. 25-34 (Jan 2002) ISSN: 0300-8177 [Print] Netherlands
• PMID: 11936844 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Enzyme Inhibitors
• Peptide Elongation Factor 2
• Insulin-Like Growth Factor I
• Nitric Oxide Synthase
• NG-Nitroarginine Methyl Ester

Topics

• Animals
• Apoptosis
• Body Weight
• Cardiomegaly (metabolism)
• DNA Fragmentation
• Disease Models, Animal
• Enzyme Inhibitors (pharmacology)
• Genetic Variation
• Heart (drug effects)
• Hemodynamics
• Hypertension (metabolism)
• Insulin-Like Growth Factor I (pharmacology)
• Male
• Myocardium (metabolism)
• NG-Nitroarginine Methyl Ester (pharmacology)
• Nitric Oxide Synthase (antagonists & inhibitors)
• Peptide Elongation Factor 2 (genetics, metabolism)
• Rats
• Rats, Wistar